PCSK9_inhibition.jpg
Size of this preview:
800 × 529 pixels
.
Other resolutions:
320 × 212 pixels
|
640 × 423 pixels
|
1,024 × 677 pixels
|
1,280 × 846 pixels
.
Summary
| Description |
English:
Monoclonal antibodies bound to PCSK9 prevent the association between PCSK9 and the LDLR. The LDLR binds the LDL particle and is internalized, and then the LDL particle is degraded in the lysosome, whereas the LDLR is recycled back to the plasma membrane.
[1]
|
| Date | |
| Source | https://doi.org/10.1194/jlr.R026658 |
| Author | Gilles Lambert, Barbara Sjouke, Benjamin Choque, John J.P. Kastelein, G. Kees Hovingh |
Licensing
This file is licensed under the
Creative Commons
Attribution 4.0 International
license.
-
You are free:
- to share – to copy, distribute and transmit the work
- to remix – to adapt the work
-
Under the following conditions:
- attribution – You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- ↑ Lambert, Gilles (2012). " The PCSK9 decade ". Journal of Lipid Research 53 (12): 2515–2524. DOI : 10.1194/jlr.R026658 . PMID 22811413 . PMC : PMC3494258 .